Hansoh Pharma’s homegrown cancer drug approved
Hansoh Pharma’s innovative cancer drug Ameile has been approved by the NMPA, the Jiangsu-based drug developer disclosed in a filing to the Hong Kong Stock Exchange.
Ameile, also known as almonertinib, is China’s first homegrown third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Regulators approved the drug for treating patients with advanced or late-stage non-small cell lung cancer (NSCLC) that is characterized by a gene mutation called T790M, exactly the type of patients that AstraZeneca’s treatment Tagrisso is designed for.
Tagrisso has been approved in China since 2017 and was added in the national reimbursement drug list in January 2019, but the emergence of Ameile gives patients a domestic treatment option as well as the government better bargaining power in future price talks.
Ameile, also known as almonertinib, is China’s first homegrown third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Regulators approved the drug for treating patients with advanced or late-stage non-small cell lung cancer (NSCLC) that is characterized by a gene mutation called T790M, exactly the type of patients that AstraZeneca’s treatment Tagrisso is designed for.
Tagrisso has been approved in China since 2017 and was added in the national reimbursement drug list in January 2019, but the emergence of Ameile gives patients a domestic treatment option as well as the government better bargaining power in future price talks.
.png)
No hay comentarios:
Publicar un comentario